This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market

After a long year and a half spent enduring the coronavirus pandemic, signs of normalcy are starting to show in many U.S. businesses and communities, thanks in part to pharmaceutical breakthroughs including vaccines. After two previously failed attempts to develop new antiviral treatments, biopharma giant Merck (NYSE: MRK) has come up with something it believes will provide care for those in need. Specifically, Merck has been collaborating with Ridgeback Biotherapeutics on a clinical development program for molnupiravir, an oral antiviral medication.